18th October 2016, SomnoMed Limited (ASX:SOM) announced today record breaking September sales (+23.8% year on year) compensated for the usually soft Northern summer months of July and August (+13.0% year on year) resulting in growth rates in unit sales of 16.9% for the first quarter of the financial year 2016/17. Total revenues were $10.94 million for the quarter, up by 13.4%.
North American unit sales followed the same seasonal pattern. Whilst July/August sales grew by 13.6%, September sales showed excellent growth of 35.3%, lifting growth for the quarter in the North America region to 20.5%. Canadian sales contributed about 5% of total North American sales. Sales through licensees were stronger than expected, contributing 16.5% of total regional sales, reflecting purchases to replace diminishing stocks.
For further information please download PDF attached:
Download this document
